These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36320173)

  • 1. Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
    Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
    J Oncol Pharm Pract; 2023 Sep; 29(6):1381-1386. PubMed ID: 36320173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line Chemotherapy Prolongs Survival in Real World Patients With Advanced Biliary Tract and Gallbladder Cancers: A Multicenter Retrospective Population-based Cohort Study.
    Zaidi A; Chandna N; Narasimhan G; Moser M; Haider K; Chalchal H; Shaw J; Ahmed S
    Am J Clin Oncol; 2021 Mar; 44(3):93-98. PubMed ID: 33350678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
    Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
    Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
    Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
    Kim RD; McDonough S; El-Khoueiry AB; Bekaii-Saab TS; Stein SM; Sahai V; Keogh GP; Kim EJ; Baron AD; Siegel AB; Barzi A; Guthrie KA; Javle M; Hochster H
    Eur J Cancer; 2020 May; 130():219-227. PubMed ID: 32234665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
    Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
    Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).
    Javle MM; Oh DY; Ikeda M; Yong WP; Hsu K; Lindmark B; McIntyre N; Firth C
    ESMO Open; 2022 Feb; 7(1):100314. PubMed ID: 34922298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
    Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with NAB
    Woodford R; Brungs D; Leighton C; Grimison P; Sjoquist KM; Becker T; Robinson S; Gebski V; Wilson K; Chantrill L; Aghmesheh M
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e220-e226. PubMed ID: 34180586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
    Larsen FO; Markussen A; Diness LV; Nielsen D
    Oncology; 2018; 94(1):19-24. PubMed ID: 28930749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
    Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
    Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
    Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
    Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.